'Why Trump's healthcare reforms won't impact our 5% dividend yield'

This month's edition features BB Biotech, one of the largest biotech investors in Europe. A Q&A with Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities.

Director of Investor Relations at the group, Claude Mikkelsen, meanwhile, offers insight into BB Biotech's investment strategy and how a combination of growth and dividend income can produce favourable investment returns.

Focus (Investment Week) is a publication that brings you face to face with a selection of the most in-demand asset managers in the UK and across Europe.  david

Click here for the Focus booklet